Download PDF
Horm Metab Res 2013; 45(12): 856-861
DOI: 10.1055/s-0033-1353197
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

Effect of Membrane Solubilization on the Inhibition of Rat and Hamster Liver Microsomal Type I 11β-Hydroxysteroid Dehydrogenase by Bile Acids

Y. Maeda
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
,
M. Funagayama
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
2   Department of Surgery I, Miyazaki University Hospital, Miyazaki, Japan
,
A. Shinohara
3   Department of Bio-resources, Division of Biotechnology, Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan
,
C. Koshimoto
3   Department of Bio-resources, Division of Biotechnology, Frontier Science Research Center, University of Miyazaki, Miyazaki, Japan
,
K. Komaki
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
,
H. Furusawa
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
,
H. Nakahara
4   Department of Radiology, Breastopia Hospital, Miyazaki, Japan
,
Y. Yasuda
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
,
E. Machida
1   Department of Surgery, Breastopia Hospital, Miyazaki, Japan
› Author Affiliations
Further Information

Publication History

received 03 April 2013

accepted 25 July 2013

Publication Date:
26 August 2013 (online)

Also available at
    Permissions and Reprints

Abstract

The aim of this study was to investigate the differences between rats and hamsters, Two of the most widely used experimental animals, with respect to the effects of microsomal membrane solubilization on the inhibition of liver 11β-hydroxysteroid dehydrogenase (11β-HSDI) enzyme by bile acids. Liver microsome fractions were prepared, and the 11β-HSDI enzymatic activity was measured using cortisone as a substrate. The substrate and various concentrations of bile acids were added to the assay mixtures. After incubation, the products were extracted and analyzed using high-performance liquid chromatography. To investigate the effect of detergent on the inhibitory effects of bile acids, we conducted inhibition tests using Triton X-100-solubilized animal liver microsomes. When solubilized microsomes were used, all bile acids inhibited 11β-HSDI from rats and hamsters to various degrees. 7α-Hydroxycholanoic acids (cholic acid and chenodeoxycholic acid) in particular had strong inhibitory activities. In hamsters, 7β-hydroxycholanoic acid (ursodeoxycholic acid) was the strongest inhibitor among the bile acids tested, although its effect was not very strong. When nonsolubilized microsomes were used, deoxycholic acid did not inhibit but rather enhanced the enzymatic activity in both animals. Microsomal content of cholesterol and phospholipids are significantly different between rats and hamsters. Species differences in bile acid inhibition of nonsolubilized microsomes might be reflected not only by structural difference of bile acids, which affect membrane solubilization and enzyme activity directly, but also species difference in microsomal membrane lipid content.

Key words

microsomes - solubilization - 11β-hydroxysteroid ­dehydrogenase - bile acid - rat - hamster
 

  • References

  • 1 Monder C, White PC. 11β-Hydroxysteroid dehydrogenase. Vitam Horm 1993; 7: 187-271
    PubMedGoogle Scholar
  • 2 Stewart PM, Krozowski Z. 11β-Hydroxysteroid dehydrogenase. Vitam Horm 1999; 57: 249-324
    PubMedGoogle Scholar
  • 3 Krozowski Z. The 11β-hydroxysteroid dehydrogenase: functions and physiological effects. Mol Cell Endocrinol 1999; 151: 121-127
    CrossrefPubMedGoogle Scholar
  • 4 Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Edwards CR, Seckle JR, Mullins JJ. 11Beta-hydroxysteroid Dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obese or stress. Proc Natl Acad Sci USA 1997; 194: 14924-14929
    PubMedGoogle Scholar
  • 5 Cooper MS, Rabbitt EH, Goddard PE, Bartlett WA, Hewison M, Stewart PM. Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure. J Bone Min Res 2002; 17: 979-986
    CrossrefPubMedGoogle Scholar
  • 6 Morton NM, Ramage L, Seckl JR. Down-regulation of adipose 11beta-hydroxysteroid dehydrogenase type I by high-fat feeding in mice: a potential adaptive mechanism conteracting metabolic disease. Endocrinology 2004; 145: 2707-2712
    CrossrefPubMedGoogle Scholar
  • 7 Valsamkis G, Anwar A, Tomlinson JW, Shackleton CH, McTerman PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S. 11Beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese male with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 4755-4761
    CrossrefPubMedGoogle Scholar
  • 8 Björkhem I. Mechanism of bile acid synthesis. In: Danielsson H, Sjövall J. (eds.) Comprehensive Biochemistry. Amsterdam: Elsevier; 1985: 231-278
    CrossrefGoogle Scholar
  • 9 Russell DW, Setchell KD. Bile acid biosynthesis. Biochemistry 1992; 31: 4737-4749
    CrossrefPubMedGoogle Scholar
  • 10 Barnes S, Gallo GA, Trash DB, Morris JS. Diagnostic value of serum bile acid estimation in liver disease. J Clin Pathol 1975; 28: 506-509
    CrossrefPubMedGoogle Scholar
  • 11 Jones AL, Schmucker DL, Mooney JS, Adler RD, Ockner RK. Morphometric analysis of rat hepatocytes after total biliary obstruction. Gastroenterology 1976; 71: 1050-1060
    PubMedGoogle Scholar
  • 12 Reichen J, Siomn FR. Cholestasis. In: Arias IM, Boyer JL, Fausto N, Jacoby WB, Schachter D, Schaffner DA. (eds.) The liver: biology and pathophysiology. New York: Raven Press; 1994: 1291-1326
    Google Scholar
  • 13 Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstone by chenodeoxycholic acid. N Engl J Med 1972; 286: 1-8
    CrossrefPubMedGoogle Scholar
  • 14 Lazaridis KN, Grores GJ, Jindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2011; 35: 134-146
    PubMedGoogle Scholar
  • 15 Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic diseases of action and therapeutic use revisited. Hepatology 2002; 36: 525-531
    CrossrefPubMedGoogle Scholar
  • 16 Zapata R, Sandoval L, Palma J, Hernández I, Ribalta J, Reyes H, Sedano M, Tohá D, Silva JJ. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-years experience. Liver Int 2005; 25: 467-468
    CrossrefPubMedGoogle Scholar
  • 17 Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, Frey FJ. Down-regulation of hepatic and renal 11β-hydroxysteroid dehydrogenase in rat with liver cirrhosis. Gastroenterology 1998; 114: 175-184
    CrossrefPubMedGoogle Scholar
  • 18 Ackermann D, Vogt B, Escher G, Dick B, Reichen J, Frey BM, Frey FJ. Inhibition of 11β-hydroxysteroid dehydrogenase by bile acids I rats with cirrhosis. Hepatology 1999; 30: 623-629
    CrossrefPubMedGoogle Scholar
  • 19 Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11β-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 2001; 108: 1299-1305
    CrossrefPubMedGoogle Scholar
  • 20 Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RAS, Frey FJ, Langer T, Odermatt A. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type I from six species. J Mol Endocrinol 2005; 35: 89-101
    CrossrefPubMedGoogle Scholar
  • 21 Diederich S, Grossmann C, Hanke B, Ouinkler M, Herrmann M, Bahr V, Oelkers W. In the research for specific inhibitors of human 11β-hydroxysteroid dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-I. Eur J Endocrinol 2000; 142: 200-207
    CrossrefPubMedGoogle Scholar
  • 22 Maeda Y, Naganuma S, Niina I, Shinihara A, Koshimoto C, Kondo K, Chijiiwa K. Effects of bile acids on rat hepatic microsomal type I 11β-hydroxysteroid dehydrogenase. Steroids 2010; 75: 164-168
    CrossrefPubMedGoogle Scholar
  • 23 Song W, Chen J, Dean WL, Redinger RN, Prough RA. Purification and characterization of hamster liver microsomal 7α-hydroxycholesterol dehydrogenase. Similarity to type I 11β-hydroxysteroid dehydrogenase. J Biol Chem 273: 16223-16228
    PubMedGoogle Scholar
  • 24 Maeda Y, Nagatomo H, Uchiyama F, Nagatomo J, Yamada M, Shiotsuki H, Ohta Y, Sato S, Kai MH, Kondo KH, Higashi S, Setoguchi T. A comparative study of the Conversion of 7-hydroxycholesterol in rabbit, guinea pig, rat, hamster, and chicken. Steroids 2002; 67: 703-708
    CrossrefPubMedGoogle Scholar
  • 25 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 26 Shiotsuki H, Maeda Y, Chijiiwa K. Purification and characterization of 7β-hydroxysteroid dehydrogenase from rabbit liver microsomes. J Steroid Biochem Mol Biol 2004; 91: 185-190
    CrossrefPubMedGoogle Scholar
  • 27 Diederich S, Ouinkler M, Mai K, Schöneshöfer M, Baehr V, Pfeiffer A, Oelkers W. In vivo activity of 11β-hydroxysteroid dehydrogenase type 1 in man: effect of predonisolone and chenodeoxycholic acid. Horm Metab Res 2011; 43: 66-71
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Lakshmi V, Monder C. Extraction of 11β-hydroxysteroid dehydrogenase from rat liver microsomes by detergents. J Steroid Biochem 1985; 22: 331-340
    CrossrefPubMedGoogle Scholar
  • 29 Ozols J. Luminal orientation and post-translational modification of the liver microsomal 11β-hydroxysteroid dehydrogenase. J Biol Chem 1995; 270: 2305-2312
    CrossrefPubMedGoogle Scholar
  • 30 Garidel P, Hildebrand A, Kauf K, Blume A. Membranolytic activity of bile salts: influence of biological membrane properties and composition. Molecules 2007; 12: 2292-2326
    CrossrefPubMedGoogle Scholar
  • 31 Férézou J, Combettes-Souverain M, Souidi M, Smith JL, Boehler N, Milliant F, Eckhardt E, Blanchard G, Riottot M, Sérougene C, Lutton C. Cholesterol, bile acid, and lipoprotein metabolism in two strains of hamster, one resistant, the other sensitive (LPN) to sucrose-induced cholelithiasis. J Lipid Res 2000; 41: 2042-2054
    PubMedGoogle Scholar
  • 32 Gilat T, Somjen GJ, Mazur Y, Leikin-frenkel A, Rosenberg R, Halpem Z, Konikoff F. Fatty acid bile acid conjugates (FABACs)-new molecules for the prevention of cholesterol crystallisation in bile. Gut 2001; 48: 75-79
    CrossrefPubMedGoogle Scholar
  • 33 Souidi M, Combettes-Souverain M, Milliat F, Eckhardt ER, Audas O, Dubrac S, Parquet M, Férézou J, Lutton C. Hamsters predisposed to sucrose-induced cholesterol gallstones (LPN strain) are more resistant to excess dietary cholesterol than hamsters that are not sensitive to cholelithiasis induction. J Nutrition 2001; 131: 1803-1811
    PubMedGoogle Scholar